Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 109,910 shares, a decline of 82.8% from the March 31st total of 640,347 shares. Based on an average daily trading volume, of 410,244 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.1% of the shares of the company are sold short.

Aprea Therapeutics Stock Up 5.2%

Aprea Therapeutics stock traded up $0.05 during mid-day trading on Friday, hitting $0.93. 40,646 shares of the company were exchanged, compared to its average volume of 1,889,890. The business has a fifty day moving average of $0.80 and a 200 day moving average of $0.98. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.22. The company has a market capitalization of $10.65 million, a PE ratio of -0.47 and a beta of 1.47.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.06. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%.The firm had revenue of $0.00 million during the quarter. Research analysts expect that Aprea Therapeutics will post -0.82 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on APRE shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Monday. Zacks Research upgraded Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. HC Wainwright cut their price target on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Wedbush reiterated an “outperform” rating and set a $7.00 price target on shares of Aprea Therapeutics in a report on Tuesday, March 31st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.10.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics at the end of the most recent reporting period. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.